Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

1 Overall, this new SELECT sub-analysis shows that semaglutide 2.4 mg substantially reduces the first ... and-height-measurements-world-obesity-day 7 Statistics Canada. An overview of weight ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...